These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 26202948)

  • 1. Notch Pathway Inhibition Using PF-03084014, a γ-Secretase Inhibitor (GSI), Enhances the Antitumor Effect of Docetaxel in Prostate Cancer.
    Cui D; Dai J; Keller JM; Mizokami A; Xia S; Keller ET
    Clin Cancer Res; 2015 Oct; 21(20):4619-29. PubMed ID: 26202948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic effect of the γ-secretase inhibitor PF-03084014 and docetaxel in breast cancer models.
    Zhang CC; Yan Z; Zong Q; Fang DD; Painter C; Zhang Q; Chen E; Lira ME; John-Baptiste A; Christensen JG
    Stem Cells Transl Med; 2013 Mar; 2(3):233-42. PubMed ID: 23408105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HepaCAM inhibits the malignant behavior of castration-resistant prostate cancer cells by downregulating Notch signaling and PF-3084014 (a γ-secretase inhibitor) partly reverses the resistance of refractory prostate cancer to docetaxel and enzalutamide in vitro.
    Du Z; Li L; Sun W; Wang X; Zhang Y; Chen Z; Yuan M; Quan Z; Liu N; Hao Y; Li T; Wang J; Luo C; Wu X
    Int J Oncol; 2018 Jul; 53(1):99-112. PubMed ID: 29658567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of selective gamma-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design.
    Wei P; Walls M; Qiu M; Ding R; Denlinger RH; Wong A; Tsaparikos K; Jani JP; Hosea N; Sands M; Randolph S; Smeal T
    Mol Cancer Ther; 2010 Jun; 9(6):1618-28. PubMed ID: 20530712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarker and pharmacologic evaluation of the γ-secretase inhibitor PF-03084014 in breast cancer models.
    Zhang CC; Pavlicek A; Zhang Q; Lira ME; Painter CL; Yan Z; Zheng X; Lee NV; Ozeck M; Qiu M; Zong Q; Lappin PB; Wong A; Rejto PA; Smeal T; Christensen JG
    Clin Cancer Res; 2012 Sep; 18(18):5008-19. PubMed ID: 22806875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor and antimetastatic activities of docetaxel are enhanced by genistein through regulation of osteoprotegerin/receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/MMP-9 signaling in prostate cancer.
    Li Y; Kucuk O; Hussain M; Abrams J; Cher ML; Sarkar FH
    Cancer Res; 2006 May; 66(9):4816-25. PubMed ID: 16651437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Docetaxel Resistance in Prostate Cancer: Taking It Up a Notch.
    Zhang T; Armstrong AJ
    Clin Cancer Res; 2015 Oct; 21(20):4505-7. PubMed ID: 26307134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of hedgehog signaling improves the anti-carcinogenic effects of docetaxel in prostate cancer.
    Mimeault M; Rachagani S; Muniyan S; Seshacharyulu P; Johansson SL; Datta K; Lin MF; Batra SK
    Oncotarget; 2015 Feb; 6(6):3887-903. PubMed ID: 25682877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of the gamma secretase inhibitor PF-03084014 in combination with docetaxel in patients with advanced triple-negative breast cancer.
    Locatelli MA; Aftimos P; Dees EC; LoRusso PM; Pegram MD; Awada A; Huang B; Cesari R; Jiang Y; Shaik MN; Kern KA; Curigliano G
    Oncotarget; 2017 Jan; 8(2):2320-2328. PubMed ID: 27906684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methylseleninic acid enhances taxane drug efficacy against human prostate cancer and down-regulates antiapoptotic proteins Bcl-XL and survivin.
    Hu H; Li GX; Wang L; Watts J; Combs GF; Lü J
    Clin Cancer Res; 2008 Feb; 14(4):1150-8. PubMed ID: 18281549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors.
    Schott AF; Landis MD; Dontu G; Griffith KA; Layman RM; Krop I; Paskett LA; Wong H; Dobrolecki LE; Lewis MT; Froehlich AM; Paranilam J; Hayes DF; Wicha MS; Chang JC
    Clin Cancer Res; 2013 Mar; 19(6):1512-24. PubMed ID: 23340294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations.
    Li X; Wu JB; Chung LW; Huang WC
    Oncotarget; 2015 Dec; 6(38):41018-32. PubMed ID: 26512780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models.
    Festuccia C; Gravina GL; D'Alessandro AM; Muzi P; Millimaggi D; Dolo V; Ricevuto E; Vicentini C; Bologna M
    Endocr Relat Cancer; 2009 Jun; 16(2):401-13. PubMed ID: 19153211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gamma secretase inhibitor enhances sensitivity to doxorubicin in MDA-MB-231 cells.
    Li ZL; Chen C; Yang Y; Wang C; Yang T; Yang X; Liu SC
    Int J Clin Exp Pathol; 2015; 8(5):4378-87. PubMed ID: 26191129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo.
    Ikezoe T; Hisatake Y; Takeuchi T; Ohtsuki Y; Yang Y; Said JW; Taguchi H; Koeffler HP
    Cancer Res; 2004 Oct; 64(20):7426-31. PubMed ID: 15492266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of Notch pathway enhances the anti-tumor effect of docetaxel in prostate cancer stem-like cells.
    Wang L; Zi H; Luo Y; Liu T; Zheng H; Xie C; Wang X; Huang X
    Stem Cell Res Ther; 2020 Jun; 11(1):258. PubMed ID: 32586404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.
    Yasumizu Y; Miyajima A; Kosaka T; Miyazaki Y; Kikuchi E; Oya M
    J Urol; 2014 Jan; 191(1):227-34. PubMed ID: 23954373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Notch signaling by γ-secretase inhibitor I enhances the cytotoxic effect of 5-FU in gastric cancer.
    Lee HW; Kim SJ; Choi IJ; Song J; Chun KH
    Clin Exp Metastasis; 2015 Aug; 32(6):593-603. PubMed ID: 26134677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined antitumor effect of γ-secretase inhibitor and ABT-737 in Notch-expressing non-small cell lung cancer.
    Sakakibara-Konishi J; Ikezawa Y; Oizumi S; Kikuchi J; Kikuchi E; Mizugaki H; Kinoshita I; Dosaka-Akita H; Nishimura M
    Int J Clin Oncol; 2017 Apr; 22(2):257-268. PubMed ID: 27816990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of PI3Kβ signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxel.
    Hancox U; Cosulich S; Hanson L; Trigwell C; Lenaghan C; Ellston R; Dry H; Crafter C; Barlaam B; Fitzek M; Smith PD; Ogilvie D; D'Cruz C; Castriotta L; Wedge SR; Ward L; Powell S; Lawson M; Davies BR; Harrington EA; Foster E; Cumberbatch M; Green S; Barry ST
    Mol Cancer Ther; 2015 Jan; 14(1):48-58. PubMed ID: 25398829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.